AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

ImmunoPrecise Antibodies ... (IPA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.59

-0.05 (-8.46%)

At close: Jan 23, 2025, 3:59 PM

0.56

-4.96%

After-hours Jan 23, 2025, 05:35 PM EST

undefined% (undefined)

Bid	0.56
Market Cap	18.41M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.75
PE Ratio (ttm)	-0.79
Forward PE	n/a
Analyst	Buy

Ask	0.57
Volume	10,328,295
Avg. Volume (20D)	6,086,471
Open	0.60
Previous Close	0.64
Day's Range	0.53 - 0.61
52-Week Range	0.33 - 2.60
Beta	undefined

About IPA

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services incl...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 7, 2002

Employees 72

Stock Exchange NASDAQ

Ticker Symbol IPA

Website https://www.ipatherapeutics.com

Analyst Forecast

According to 2 analyst ratings, the average rating for IPA stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 743.60% from the latest price.

Buy 50.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

ImmunoPrecise Antibodies Ltd. is scheduled to release its earnings on Mar 13, 2025, before market opens.
Analysts project revenue of $4.93M, reflecting a 8.23% YoY growth and earnings per share of -0.06, making a -25.00% decrease YoY.

Why Price Moved

1 day ago New

+30.73%

ImmunoPrecise Antibodies shares are trading higher... Unlock content with Pro Subscription

4 months ago

-19.12%

ImmunoPrecise Antibodies shares are trading lower after the company reported worse-than-expected Q1 financial results.

News

1 day ago · businesswire.com

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhanc...

6 days ago · businesswire.com

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set to t...

3 weeks ago · businesswire.com

IPA Announces Resignation of Chief Financial Officer

AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective J...

3 weeks ago · businesswire.com

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

SANTA MARIA, Calif.--(BUSINESS WIRE)-- #apartmentinvestments--$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors.

1 month ago · businesswire.com

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pl...

1 month ago · businesswire.com

IPA to Present at The Microcap Conference 2025

1 month ago · zacks.com

QIAGEN Stock Gains Following the Latest Launch of IPA Interpret

QGEN announces the launch of IPA Interpret to extend the analysis capabilities of a human-curated knowledge base with AI technology.

1 month ago · businesswire.com

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new featu...

1 month ago · seekingalpha.com

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2025 Earnings Conference Call December 10, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Sw...

1 month ago · zacks.com

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q2 Loss, Misses Revenue Estimates

ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05.

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a signifi...

2 months ago · businesswire.com

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

FRIEDBERG, Germany--(BUSINESS WIRE)--voxeljet AG (OTCMKTS: VJTTY) (the ‘Company', ‘voxeljet', or ‘we'), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial an...

2 months ago · businesswire.com

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces t...

2 months ago · businesswire.com

ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. ("IPA" or the "Company") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces i...